Avid Bioservices Inc. (NASDAQ:CDMOP) and InflaRx N.V. (NASDAQ:IFRX) compete with each other in the Biotechnology sector. We will analyze and contrast their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation.
Earnings & Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Avid Bioservices Inc.||43.49M||4.75||16.11M||-0.31||0.00|
Demonstrates Avid Bioservices Inc. and InflaRx N.V. earnings per share, gross revenue and valuation.
Table 2 hightlights the return on equity, return on assets and net margins of the two companies.
|Net Margins||Return on Equity||Return on Assets|
|Avid Bioservices Inc.||-37.04%||0%||0%|
The next table highlights the shown recommendations and ratings for Avid Bioservices Inc. and InflaRx N.V.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Avid Bioservices Inc.||0||0||0||0.00|
Competitively the consensus price target of InflaRx N.V. is $58, which is potential 40.13% upside.
Institutional and Insider Ownership
Avid Bioservices Inc. and InflaRx N.V. has shares owned by institutional investors as follows: 0.72% and 58.4%. Avid Bioservices Inc.’s share owned by insiders are 7.06%.
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Avid Bioservices Inc.||0.85%||1.09%||8.25%||1.61%||6.87%||3.88%|
For the past year Avid Bioservices Inc.’s stock price has smaller growth than InflaRx N.V.
InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was founded in 2007 and is headquartered in Jena, Germany.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.